AS

Anilkumar Shridhar Mulye

Active Director Director DIN 10772965
DIN 10772965 First appointment Sep 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 9 active board seats
Total affiliations 9 Since Sep 2024
Shareholding value •••• Premium profile

About Anilkumar Shridhar Mulye

Data last updated:

Anilkumar Shridhar Mulye is a Director at Enem Nostrum Remedies Private Limited (since 2024), Director at Nli Healthcare (India) Private Limited (since 2024) and Director at Nexgen Healthcare Private Limited (since 2024), and holds 6 more current directorships. The companies operate in Pharma, Information Technology and Life Sciences. The 8 current companies with reported revenue have a combined latest revenue of ₹43.05 Cr; the largest is Enem Nostrum Remedies Private Limited at ₹42.33 Cr (FY 2025).

DIN 10772965
Primary Designation Director
Industry Pharma
First Appointment 11 Sep 2024
Oldest Company Age 26 yrs
Largest company Enem Nostrum Remedies Private Limited · ₹42.33 Cr (FY 2025)
Combined revenue ₹43.05 Cr across 8 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Sep 20242001₹42.33 Cr (FY 2025)Active
Director16 Sep 20242019₹58.9 Lakh (FY 2024)Active
Nexgen Healthcare Private Limited U24230MH2004PTC148417
Director11 Sep 20242004₹6.3 Lakh (FY 2025)Active
Symmetrix Biotech Private Limited U24239MH2007PTC167239
Director11 Sep 20242007₹5.5 Lakh (FY 2025)Active
Director16 Sep 20242011₹35,170 (FY 2023)Active
Nostrum Technologies Private Limited U72900MH2007PTC173481
Director16 Sep 20242007₹21,450 (FY 2022)Active
Director11 Sep 20242000₹20,120 (FY 2022)Active
Umala Healthcare Private Limited U85100MH2012PTC232083
Director11 Sep 20242012₹15,350 (FY 2023)Active

Directorship timeline

Open interactive timeline →
Enem Nostrum Remedies Private Limited
Nostrum Technologies Private Limited
Nli Healthcare (India) Private Limited
Vidit Pharma Sciences Private Limited
Premium access

Shareholding and investment profile for Anilkumar Shridhar Mulye

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anilkumar Shridhar Mulye

Anilkumar Shridhar Mulye currently holds 9 directorships: Enem Nostrum Remedies Private Limited (Director, since 16 Sep 2024, revenue ₹42.33 Cr (FY 2025)); Nli Healthcare (India) Private Limited (Director, since 16 Sep 2024, revenue ₹58.9 Lakh (FY 2024)); Nexgen Healthcare Private Limited (Director, since 11 Sep 2024, revenue ₹6.3 Lakh (FY 2025)); Symmetrix Biotech Private Limited (Director, since 11 Sep 2024, revenue ₹5.5 Lakh (FY 2025)); Bombay Bio-Research Centre Private Limited (Director, since 16 Sep 2024, revenue ₹35,170 (FY 2023)); and 4 more.

Anilkumar Shridhar Mulye was first appointed on 11 Sep 2024 as Director at Nexgen Healthcare Private Limited.

The 8 current companies of Anilkumar Shridhar Mulye that report revenue have a combined latest revenue of ₹43.05 Cr: Enem Nostrum Remedies Private Limited ₹42.33 Cr (FY 2025); Nli Healthcare (India) Private Limited ₹58.9 Lakh (FY 2024); Nexgen Healthcare Private Limited ₹6.3 Lakh (FY 2025); Symmetrix Biotech Private Limited ₹5.5 Lakh (FY 2025); Bombay Bio-Research Centre Private Limited ₹35,170 (FY 2023); and 3 more.

The current boards of Anilkumar Shridhar Mulye's companies include Shraddha Vinayak Dhamankar (Enem Nostrum Remedies Private Limited), Kaushik Krishnakant Vyas (Symmetrix Biotech Private Limited), Rama Ravikiran Marathe (Symmetrix Biotech Private Limited), Yatindra Prashar (Symmetrix Biotech Private Limited), Nirmal Vasant Mulye (Bombay Bio-Research Centre Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available